JP2022505670A5 - - Google Patents

Info

Publication number
JP2022505670A5
JP2022505670A5 JP2021522086A JP2021522086A JP2022505670A5 JP 2022505670 A5 JP2022505670 A5 JP 2022505670A5 JP 2021522086 A JP2021522086 A JP 2021522086A JP 2021522086 A JP2021522086 A JP 2021522086A JP 2022505670 A5 JP2022505670 A5 JP 2022505670A5
Authority
JP
Japan
Prior art keywords
crystalline salt
salt
xrpd
pattern
theta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021522086A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022505670A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/059385 external-priority patent/WO2020092898A1/en
Publication of JP2022505670A publication Critical patent/JP2022505670A/ja
Publication of JP2022505670A5 publication Critical patent/JP2022505670A5/ja
Priority to JP2024085295A priority Critical patent/JP2024109860A/ja
Pending legal-status Critical Current

Links

JP2021522086A 2018-11-02 2019-11-01 血漿カリクレイン阻害剤の結晶塩 Pending JP2022505670A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024085295A JP2024109860A (ja) 2018-11-02 2024-05-27 血漿カリクレイン阻害剤の結晶塩

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862754983P 2018-11-02 2018-11-02
US62/754,983 2018-11-02
PCT/US2019/059385 WO2020092898A1 (en) 2018-11-02 2019-11-01 Crystalline salts of a plasma kallikrein inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024085295A Division JP2024109860A (ja) 2018-11-02 2024-05-27 血漿カリクレイン阻害剤の結晶塩

Publications (2)

Publication Number Publication Date
JP2022505670A JP2022505670A (ja) 2022-01-14
JP2022505670A5 true JP2022505670A5 (cg-RX-API-DMAC7.html) 2022-10-17

Family

ID=70457981

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021522086A Pending JP2022505670A (ja) 2018-11-02 2019-11-01 血漿カリクレイン阻害剤の結晶塩
JP2024085295A Pending JP2024109860A (ja) 2018-11-02 2024-05-27 血漿カリクレイン阻害剤の結晶塩

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024085295A Pending JP2024109860A (ja) 2018-11-02 2024-05-27 血漿カリクレイン阻害剤の結晶塩

Country Status (22)

Country Link
US (11) US10662160B1 (cg-RX-API-DMAC7.html)
EP (1) EP3873463A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022505670A (cg-RX-API-DMAC7.html)
KR (1) KR102810837B1 (cg-RX-API-DMAC7.html)
CN (1) CN112969458A (cg-RX-API-DMAC7.html)
AR (1) AR116951A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019374115B8 (cg-RX-API-DMAC7.html)
BR (1) BR112021008249A2 (cg-RX-API-DMAC7.html)
CA (1) CA3117123A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021001094A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021007172A2 (cg-RX-API-DMAC7.html)
EA (1) EA202191192A1 (cg-RX-API-DMAC7.html)
IL (2) IL322896A (cg-RX-API-DMAC7.html)
MA (1) MA54087A (cg-RX-API-DMAC7.html)
MX (1) MX2021004917A (cg-RX-API-DMAC7.html)
PE (1) PE20211280A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021550883A1 (cg-RX-API-DMAC7.html)
PY (1) PY1991831A (cg-RX-API-DMAC7.html)
SG (1) SG11202103804TA (cg-RX-API-DMAC7.html)
TW (1) TW202031255A (cg-RX-API-DMAC7.html)
UY (1) UY38438A (cg-RX-API-DMAC7.html)
WO (1) WO2020092898A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20221373T1 (hr) 2014-03-07 2023-01-06 Biocryst Pharmaceuticals, Inc. Supstituirani pirazoli kao inhibitori kalikreina u ljudskoj plazmi
UY38438A (es) 2018-11-02 2020-05-29 Biocryst Pharm Inc Sales cristalinas de un inhibidor de calicreína plasmática
WO2021025969A1 (en) * 2019-08-02 2021-02-11 Teva Pharmaceuticals International Gmbh Solid state forms of berotralstat
CN116375648A (zh) * 2023-03-22 2023-07-04 苏州农平科技发展有限公司 贝罗司他中间体的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) * 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
EP1828187A2 (en) 2004-12-15 2007-09-05 Brystol-Myers Squibb Company Crystalline forms of a factor xa inhibitor
CN101495468A (zh) * 2006-07-31 2009-07-29 艾克提弗赛特制药股份有限公司 血浆激肽释放酶抑制剂
EP2051707B1 (en) 2006-07-31 2013-07-17 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
CN102892763B (zh) * 2010-05-19 2016-03-09 桑多斯股份公司 泊沙康唑及泊沙康唑中间体的纯化
JP5808818B2 (ja) 2010-11-25 2015-11-10 ラツィオファーム・ゲーエムベーハー アファチニブの新規塩及び多形形態
GB201212081D0 (en) * 2012-07-06 2012-08-22 Kalvista Pharmaceuticals Ltd New polymorph
HRP20221373T1 (hr) * 2014-03-07 2023-01-06 Biocryst Pharmaceuticals, Inc. Supstituirani pirazoli kao inhibitori kalikreina u ljudskoj plazmi
FI4019022T3 (fi) 2015-10-01 2024-04-19 Biocryst Pharm Inc Ihmisen plasman kallikreiinin estäjiä
UY38438A (es) 2018-11-02 2020-05-29 Biocryst Pharm Inc Sales cristalinas de un inhibidor de calicreína plasmática
EP4010320A4 (en) 2019-08-06 2023-08-16 Biocryst Pharmaceuticals, Inc. Process-scale synthesis of a plasma kallikrein inhibitor

Similar Documents

Publication Publication Date Title
JP2021169499A5 (cg-RX-API-DMAC7.html)
BR112014003245B1 (pt) Composto de ácido n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil] acetamida metanossulfônico monohidratado cristalino, método para a sintetização do mesmo, e composição farmacêutica contendo o mesmo
WO2011141933A2 (en) Process for preparation of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid and its pharmaceutically acceptable salts
JPH07188150A (ja) アリールおよびヘテロ環シアノグアニジン誘導体
JP2022530718A (ja) 三環式化合物及びその製造方法と使用
CN101676266A (zh) 氘代的ω-二苯基脲及衍生物以及包含该化合物的药物组合物
CN105085360A (zh) 一种高纯度维格列汀的制备方法
WO1995007263A1 (de) 1,2-di(het)aryl-benzimidazol derivate, deren herstellung und deren verwendung als prostazyklin-(pgi2)-mimetika
EP3100735B1 (en) Crystalline fosaprepitant dicyclohexylamine salt and its preparation
CN103108874A (zh) 用于制备双嘧达莫的方法
CN107698574B (zh) 一种高纯度阿瑞匹坦的精制制备工艺
JP5341521B2 (ja) タンパク質と結合パートナーとの相互作用を阻害するための化合物及び方法
JP2025536416A5 (cg-RX-API-DMAC7.html)
EP3755693B1 (en) Agents and methods for treating dysproliferative diseases
JP2002520404A (ja) 多環チアゾリジン−2−イリデンアミン、その調製方法および医薬としてのその使用
WO2025176185A1 (zh) 一种braf抑制剂的制备方法
WO2014128094A1 (en) Asymmetric synthesis of a substituted pyrrolidine-2-carboxamide
WO2019037161A1 (zh) 一种合成氯法齐明关键中间体n-(4-氯苯基)-1,2-苯二胺的方法
CN107879979B (zh) 一种右美托咪定的制备方法
JP7815213B2 (ja) ベンジルアミン誘導体、その調製方法およびその用途
JP2022524741A5 (cg-RX-API-DMAC7.html)
CN113387934B (zh) 一种多芳基取代咪唑衍生物及其制备方法与应用
CN112851577A (zh) 瑞戈非尼的制备方法
KR102757744B1 (ko) 유기 키랄 촉매 화합물 및 친환경 용매를 이용한 키랄 말레이미드 유도체의 제조방법
CN114957098B (zh) 一种制备喷他佐辛中间体的方法